Drug Profile
Futibatinib - Taiho Oncology/Taiho Pharmaceutical
Alternative Names: LYTGOBI; TAS 120Latest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Developer Taiho Oncology; Taiho Pharmaceutical
- Class Amines; Antineoplastics; Ketones; Phenyl ethers; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Biliary cancer
- Registered Cholangiocarcinoma
- Phase II Breast cancer; Gastric cancer; Lymphoid leukaemia; Myeloid leukaemia; Oesophageal cancer; Solid tumours; Urogenital cancer
- Phase I/II Non-small cell lung cancer
- Preclinical Rhabdomyosarcoma
Most Recent Events
- 05 Dec 2023 Efficacy and adverse event data from a phase II trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 20 Oct 2023 Taiho Pharmaceutical completes a phase Ib trial in Oesophageal cancer and non small cell lung cancer in Japan prior to October 2023 (jRCT2080224975)
- 30 Sep 2023 Phase-I clinical trials in Solid tumours (Combination therapy with zimberelimab) in Japan prior to September 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)